<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1612211484
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Alix
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PEMETREXED
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Lyophilisate for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2595.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alix injection is a medicine used in the treatment of cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alix injection is given in combination with&nbsp; Cisplatin,&nbsp; another&nbsp; anti-cancer&nbsp; medicine, as treatment for malignant pleural mesothelioma, a form of cancer that affects the&nbsp; lining of the lung, to patients who have not received prior chemotherapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alix injection is also given in combination with&nbsp; Cisplatin&nbsp; for&nbsp; the initial treatment&nbsp; of patients with advanced stage of lung cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alix injection can be prescribed to you if you have lung cancer at an advanced stage if your disease has responded to treatment or it remains largely unchanged after initial chemotherapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alix injection is also a treatment for patients with advanced stage of lung cancer</p><p>&nbsp;</p><p>whose disease has progressed after other initial chemotherapy has been used.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp; Do not use ALIX injection</p><p>-&nbsp; If you are allergic (hypersensitive) to Pemetrexed or any of the other ingredients of Pemetrexed injection</p><p>-&nbsp; If you are breast-feeding; you must discontinue breast-feeding during treatment with Alix injection.</p><p>-&nbsp; If you have recently received or are about to receive a vaccine against yellow fever.</p><p>Warnings and Precautions</p><p><u>Talk to your doctor or hospital pharmacist before receiving Alix injection.</u></p><p>If you currently have or have previously had problems with your kidneys, talk to your doctor or hospital pharmacist as you may not be able to receive Alix injection.</p><p>Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive Alix injection. Your doctor may decide to change the dose or delay treating you depending on your general condition and if your blood cell counts are too low. If you are also receiving cisplatin, your doctor will make sure that you are properly hydrated and receive appropriate treatment before and after receiving cisplatin to prevent vomiting.</p><p>If you have had or are going to have radiation therapy, please tell your doctor, as there may be an early or late radiation reaction with Alix injection.</p><p>If you have been recently vaccinated, please tell your doctor, as this can possibly cause bad effects with Alix injection.</p><p>If you have heart disease or a history of heart disease, please tell your doctor.</p><p>If you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you Alix injection.</p><p>&nbsp;</p><p>Children and adolescents</p><p>This medicine should not be used in children or adolescents, since there is no experience with this medicine in children and adolescents under 18 years of age.</p><p>Other medicines and ALIX injection</p><p>Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called &ldquo;nonsteroidal anti-inflammatory drugs&rdquo; (NSAIDs), including medicines purchased without a doctor&rsquo;s prescription (such as ibuprofen). There are many sorts of NSAIDs with different durations of activity. Based on the planned date of your infusion of Alix Injection and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them. If you are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs.</p><p>Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>Pregnancy</p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor. The use of Alix injection should be avoided during pregnancy. Your doctor will discuss with you the potential risk of taking Alix injection during pregnancy. Women must use effective contraception during treatment with Alix injection.</p><p>Breast-feeding</p><p>If you are breast-feeding, tell your doctor.</p><p>Breast-feeding must be discontinued during Alix injection treatment.</p><p>&nbsp;</p><p>Fertility</p><p>Men are advised not to father a child during and up to 6 months following treatment with Alix injection and should therefore use effective contraception during treatment with Alix injection and for up to 6 months afterwards. If you would like to father a child during the treatment or in the 6 months following receipt of treatment, seek advice from your doctor or pharmacist. You may&nbsp; want to seek counseling on sperm storage before starting your therapy.</p><p>Driving and using machines</p><p>Pemetrexed injection may make you feel tired. Be careful when driving a car or using machines.</p><p>Pemetrexed injection contains sodium</p><p>This medicine contains 54 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 2.7 % of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The dose of Pemetrexed injection is 500 milligrams for every square meter of your body&rsquo;s surface area. Your height and weight are measured to work out the surface area of&nbsp; your body. Your doctor will use this body surface area to&nbsp; work&nbsp; out&nbsp; the&nbsp; right&nbsp; dose&nbsp; for&nbsp; you.&nbsp; This dose may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition. A hospital pharmacist, nurse or doctor&nbsp; will have&nbsp; mixed the&nbsp; Pemetrexed injection powder with 9 mg/ml&nbsp; (0.9 %) sodium&nbsp; chloride&nbsp; solution&nbsp;&nbsp; for injection before it is given to you.</p><p>You will always&nbsp; receive&nbsp; Alix&nbsp; injection&nbsp; by&nbsp; infusion&nbsp; into&nbsp; one&nbsp; of&nbsp; your&nbsp; veins.&nbsp; The&nbsp; infusion will last approximately 10 minutes.</p><p>When using Alix injection in combination with cisplatin:</p><p>The doctor or hospital pharmacist will work out the dose you need based on your height and weight. Cisplatin is also given by infusion into one of your veins, and is&nbsp; given&nbsp; approximately 30 minutes after the infusion of Alix injection has finished. The infusion of cisplatin will last approximately 2 hours.</p><p>You should usually receive your infusion once every 3 weeks.</p><p>Additional medicines: Corticosteroids: your doctor will prescribe you steroid tablets (equivalent to 4 milligram of dexamethasone twice a day) that you will need to take on the day before, on the day of, and the day after Alix injection treatment. This medicine is given&nbsp; to you to reduce the frequency and severity of skin reactions that you &nbsp;may&nbsp; experience&nbsp; during your anticancer treatment.</p><p>Vitamin supplementation: your doctor will prescribe you oral folic acid (vitamin) or a multivitamin containing folic acid (350 to 1000 micrograms) that you must take once a day while you are taking Pemetrexed injection. You must take at least 5 doses during the seven days before the first dose of Pemetrexed injection. You must continue taking the folic acid&nbsp; for 21 days after the last dose of Pemetrexed injection You will also receive an injection of vitamin B12 (1000 micrograms) in the week before administration of Pemetrexed injection and then approximately every 9 weeks (corresponding to 3 courses of Pemetrexed injection treatment). Vitamin B12 and folic acid are&nbsp; given to&nbsp; you&nbsp; to&nbsp; reduce&nbsp; the&nbsp; possible&nbsp; toxic effects of the anticancer treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. You must contact your doctor immediately if you notice any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever or infection (common): if you&nbsp; have&nbsp; a temperature of 38&ordm;C&nbsp; or&nbsp; greater,&nbsp; sweating or other signs of infection(since you might have less white blood cells than normal&nbsp; which is very common). Infection (sepsis) may be severe and could lead to death.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you start feeling chest pain (common) or having a fast heart rate (uncommon).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have pain, redness, swelling or sores in your mouth (very common).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction: if you develop skin rash (very common) / burning or prickling sensation (common), or fever (common). Rarely, skin reactions may be severe and could lead to death.</p><p>Contact your doctor if you get a severe rash, or itching, or blistering (Stevens-Johnson Syndrome or Toxic epidermal necrolysis).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience tiredness, feeling faint, becoming easily breathless or if you look pale (since you might have less haemoglobin than normal which is very common).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising (since you might have less platelets than normal which is very common).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience sudden breathlessness, intense chest pain or cough with bloody sputum (uncommon) (may indicate a blood clot in the blood vessels of the lungs).</p><p>Side effects with Alix Injection may include:</p><p>Very common (may affect more than 1 in 10 people)</p><p>Infection</p><p>Pharyngitis (a sore throat)</p><p>Low number of neutrophil granulocytes (a type of white blood cell) Low white blood cells</p><p>Low haemoglobin level</p><p>Pain, redness, swelling or sores in your mouth Loss of appetite</p><p>Vomiting Diarrhoea Nausea Skin rash Flaking skin</p><p>Abnormal blood tests showing reduced functionality of kidneys Fatigue (tiredness)</p><p>Common (may affect up to 1 in 10 people)</p><p>Blood infection</p><p>Fever with low number of neutrophil granulocytes (a type of white blood cell) Low platelet count</p><p>Allergic reaction Loss of body fluids Taste change</p><p>Damage to the motor nerves which may cause muscle weakness and atrophy (wasting) primary in the arms and legs)</p><p>Damage to the sensory nerves that may cause lost of sensation, burning pain and unsteady gait Dizziness</p><p>Inflammation or swelling of the conjunctiva (the membrane that lines the eyelids and covers the white of the eye</p><p>Dry eye Watery eyes</p><p>&nbsp;</p><p>Dryness of the conjunctiva (the membrane that lines the eyelids and covers the white of the eye) and cornea (the clear layer in front of the iris and pupil.</p><p>Swelling of the eyelids</p><p>Eye disorder with dryness, tearing, irritation, and/or pain</p><p>Cardiac Failure (Condition that affects the pumping power of your heart muscles) Irregular heart rhythm</p><p>Indigestion Constipation Abdominal pain</p><p>Liver: increases in the chemicals in the blood made by the liver Increased skin pigmentation</p><p>Itchy skin</p><p>Rash on the body where each mark resembles a bulls eye Hair loss</p><p>Hives</p><p>Kidney stop working</p><p>Reduced functionality of kidney Fever</p><p>Pain</p><p>Excess fluid in body tissue, causing swelling Chest pain</p><p>Inflammation and ulceration of the mucous membranes lining the digestive tract</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>Reduction in the number of red, white blood cells and platelets Stroke Type of stroke when an artery to the brain is blocked Bleeding inside the skull</p><p>Angina (Chest pain caused by reduced blood flow to the heart) Heart attack</p><p>Narrowing or blockage of the coronary arteries Abnormal heart rythm Deficient blood distribution to the limbs</p><p>Blockage in one of the pulmonary arteries in your lungs</p><p>&nbsp;</p><p>Inflammation and scarring of the lining of the lungs with breathing problems</p><p>Passage of bright red blood from the anus Bleeding in the gastrointestinal tract Ruptured bowel Inflammation of the lining of the oesophagus</p><p>Inflammation of the lining of the large bowel, which may be accompanied by intestinal or rectal bleeding (seen only in combination with Cisplatin) Inflammation, Edema, erythema, and erosion of the mucosal surface of the oesophagus caused by radiation therapy Inflammation of the lung caused by radiation therapy</p><p>Rare (may affect up to 1 in 1,000 people)</p><p>Destruction of red blood cells</p><p>Anaphylactic shock (severe allergic reaction) Inflammatory condition of the liver</p><p>Redness of the skin</p><p>Skin rash that develops throughout a previously irradiated area</p><p>Very rare (affect up to 1 of 10 000 people)</p><p>Infections of skin and soft tissues</p><p>Stevens-Johnson syndrome (a type of severe skin and mucous membranes reaction that may be life threatening)</p><p>Toxic epidermal necrolysis (a type of severe skin reaction that may be life threatening) Autoimmune disorder that results in skin rashes and blistering on the legs, arms, and abdomen Inflammation of the skin characterized by the presence of bullae which are filled with fluid Skin fragility, blisters and erosions and skin scarring</p><p>Redness, pain and swelling mainly of the lower limbs Inflammation of the skin and fat beneath the skin (pseudo cellulitis) Inflammation of the skin (dermatitis)</p><p>Skin to become inflamed, itchy, red, cracked, and rough Intensely itchy spots</p><p>Not known: frequency cannot be estimated from the available data</p><p>Form of diabetes primarily due to pathology of the kidney</p><p>Disorder of the kidneys involving the death of tubular epithelial cells that form the renal tubules You might have any of these symptoms and/or conditions. You must tell your doctor as soon as possible when you start experiencing any of these side effects.</p><p>If you are concerned about any side effects, talk to your doctor.</p><p>&nbsp;</p><p>Reporting of side effects</p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:88.2pt;margin-top:19.3pt;width:382.6pt;height:124.7pt;z-index:-251658240;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:63.05pt;
     margin-bottom:0in;margin-left:5.15pt;margin-bottom:.0001pt;line-height:
     150%'>The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax:
     +966-11-205-7662<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.15pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt'>o Call NPC at
     +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.8pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Toll free phone:<span
     style='letter-spacing:-.05pt'> </span>8002490000<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:7.0pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>E-mail:<span
     style='letter-spacing:-.55pt'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:blue;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:7.0pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:<span
     style='letter-spacing:-.3pt'> </span><a href="http://www.sfda.gov.sa/npc"><span
     style='color:blue;text-decoration:none;text-underline:none'>www.sfda.gov.sa/npc</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="515" height="171" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662
o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
o	Toll free phone: 8002490000
o	E-mail: npc.drug@sfda.gov.sa
o	Website: www.sfda.gov.sa/npc
" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>o Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the vial and on the box. The expiry date</p><p><strong>Reconstituted dilution: </strong>To reconstitute 20 mL of 0.9% Sodium chloride Injection (Preservative free) to make a solution containing 25mg/mL Pemetrexed. Reconstituted solution must be further diluted before use.</p><p>The appropriate volume of reconstituted Pemetrexed solution must be further diluted to 100 ml with sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, and administered as an intravenous infusion over 10 minutes.</p><p>After reconstitution<em>:</em></p><p>Reconstituted and Infusion Solutions: The product should be used immediately. When prepared as directed, chemical and physical in-use stability of reconstituted and infusion solutions of Pemetrexed were demonstrated for 24 hours at refrigerated temperature.</p><p>This medicine is for single use only; any unused solution must be disposed of in accordance with local requirement.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Pemetrexed Disodium 2.5 Hydrate</p><p>Each vial contains Pemetrexed Disodium 2.5 Hydrate equivalent to Pemetrexed 500mg.</p><p>The other ingredients are: Mannitol (Pearlitol PF), Sodium Hydroxide, Hydrochloric acid, Water for Injection and Nitrogen gas</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Pemetrexed Injection looks like?
White to Either light yellow or green-yellow lyophilized cake.
How supplied:
Pemetrexed for Injection 500mg are supplied in glass Vials

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 2215</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي اليكس حقن إلى مجموعة من الأدوية التي تستخدم في علاج السرطان .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء حقن اليكس بالإضافة إلى سيسبلاتين (وهو دواء آخر مضاد للسرطان) ، كعلاج لسرطان الغشاء البللوري الخبيث ، وهو شكل من أشكال السرطان يؤثر على بطانة الرئة ، في المرضى الذين لم يتلقوا العلاج الكيميائي مسبقا .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء اليكس حقن أيضا مع سيسبلاتين كعلاج مبدئي للمرضى الذين يعانون من مرحلة متقدمة من سرطان الرئة .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن وصف اليكس حقن لك إذا كان لديك سرطان الرئة في مرحلة متقدمة وإذا كانت حالتك قد استجابت للعلاج أو لم تتغير إلى حد كبير بعد العلاج الكيميائي الأولي .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليكس حقن هو أيضا علاج للمرضى الذين يعانون من مرحلة متقدمة من سرطان الرئة والذي تطور بعد تناول العلاج الكيميائي الأولي الآخر .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال </strong><strong>اليكس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية (شديدة الحساسية) لبيمتريكسد ثنائي الصوديوم 2,5 هيدرات أو أي من المكونات الأخرى لحقن اليكس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت في مرحلة الرضاعة الطبيعية ؛ يجب عليك التوقف عن الرضاعة الطبيعية أثناء العلاج بتناول اليكس حقن .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تناولت مؤخراً أو على وشك الحصول على عقار ضد الحمى الصفراء .</p><p dir="RTL"><strong>التحذيرات والإحتياطات </strong></p><p dir="RTL">تحدث إلى طبيبك أو صيدلي المستشفى قبل تناول اليكس حقن:</p><p dir="RTL">إذا كنت تعاني حاليًا أو مسبقا من مشاكل في الكليتين ، تحدث إلى طبيبك أو صيدلي المستشفى حيث قد لا تتمكن من تناول اليكس حقن .</p><p dir="RTL">قبل كل عملية ضخ وريدي ، سيتم سحب عينات من الدم لتقييم وظائف الكلى والكبد لديك وللتحقق من وجود ما يكفي من خلايا الدم كي تتناول اليكس حقن . قد يقرر طبيبك تغيير الجرعة أو التأخير في علاجك وفقًا لحالتك العامة وإذا كانت أعداد خلايا الدم لديك منخفضة جدًا . إذا كنت تتلقى أيضا سيسبلاتين ، فإن طبيبك سوف يتأكد من أنك تناولت سوائل كافية بشكل صحيح وأنك تتلقى العلاج المناسب قبل وبعد تتناول سيسبلاتين لمنع حدوث القيء .</p><p dir="RTL">إذا كنت قد تلقيت أو ستتلقى علاج إشعاعي ، فيرجى إخبار طبيبك ، حيث قد يكون هناك تفاعل إشعاعي مبكر أو متأخر مع تناول اليكس حقن .</p><p dir="RTL">إذا كنت قد تناولت مؤخرا تطعيمًا ، فيرجى إخبار طبيبك ، لأن ذلك قد يتسبب في آثار سيئة على تناول اليكس حقن .</p><p dir="RTL">إذا كنت تعاني حاليا أو مسبقا من مرض بالقلب ، يرجى إخبار طبيبك .</p><p dir="RTL">إذا كان لديك تجمع للسوائل حول رئتيك ، فقد يقرر طبيبك إزالة السائل قبل إعطائك اليكس حقن .</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوجد أي استخدام ذات الصلة اليكس حقن في الأطفال .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول الأدوية الأخرى مع </strong><strong>اليكس </strong><strong>حقن</strong></p><p dir="RTL">يجب أن تخبر طبيبك إذا كنت تتناول أي دواء للألم أو الالتهاب (تورم) ، مثل الأدوية التي تسمى &quot;الأدوية المضادة للالتهاب غير الستيرويدية&quot; (NSAIDs) ، بما في ذلك الأدوية التي تم شراؤها بدون وصفة طبية (مثل الأيبوبروفين) . هناك أنواع كثيرة من مضادات الالتهاب غير الستيروئيدية مع فترات مختلفة من الفاعلية . استنادًا إلى الجدول الزمني المخصص للتسريب الوريدي اليكس حقن و / أو حالة وظائف الكلى ، يجب أن ينصحك طبيبك بالأدوية التي يمكنك تناولها ومتى يمكنك تناولها . إذا لم تكن متأكداً ، فاطلب من طبيبك أو الصيدلي إذا كان أي من الأدوية الخاصة بك تعد من مضادات الالتهاب غير الستيروئيدية .</p><p dir="RTL">من فضلك أخبر طبيبك أو صيدلي المستشفى إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى ، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية .</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">إذا كنت حاملاً أو تفكرين في الحمل ، أخبر طبيبك . يجب تجنب استخدام اليكس حقن أثناء الحمل . سوف يناقش طبيبك معك المخاطر المحتملة لتناول اليكس حقن أثناء الحمل . يجب على النساء استخدام وسائل منع الحمل الفعالة خلال العلاج بتناول اليكس حقن .</p><p dir="RTL"><strong>&nbsp;الرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت تقومين بالرضاعة الطبيعية ، أخبر طبيبك .</p><p dir="RTL">يجب التوقف عن الرضاعة الطبيعية خلال فترة العلاج بتناول اليكس حقن<strong> .</strong></p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">يُنصح الرجال بعدم الإنجاب خلال فترة تصل إلى 6 أشهر بعد العلاج باستخدام اليكس حقن ولذلك يجب استخدام وسائل منع الحمل الفعالة أثناء العلاج باستخدام اليكس حقن ولمدة تصل إلى 6 أشهر بعد ذلك . إذا كنت ترغب في إنجاب طفل أثناء العلاج أو خلال الستة أشهر التالية لتلقي العلاج ، فاطلب النصيحة من طبيبك أو الصيدلي . قد ترغب في طلب المشورة عن تخزين الحيوانات المنوية قبل بدء العلاج .</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">تناول اليكس حقن قد يجعلك تشعر بالتعب . كن حذرا عند قيادة السيارة أو استخدام الآلات .</p><p dir="RTL"><strong>محتوي </strong><strong>اليكس حقن</strong><strong> </strong><strong>من الصوديوم</strong></p><p dir="RTL">يحتوي اليكس حقن على حوالي 54 ملغم من الصوديوم لكل قارورة . فيجب أخذ الاعتبار من قبل المرضى اللذين يتناولون نظام غذائي خافض للصوديوم .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جرعة اليكس حقن هي 500 ملغم لكل متر مربع من مساحة سطح الجسم . يتم قياس الطول والوزن الخاصين بك لتحديد مساحة سطح الجسم . سيستخدم طبيبك مساحة سطح الجسم لتحديد الجرعة المناسبة لك . قد يتم تعديل هذه الجرعة ، أو قد يتأخر العلاج اعتمادًا على عدد خلايا الدم وعلى حالتك العامة . سيقوم الطبيب أو الصيدلي أو الممرضة بخلط مسحوق اليكس بمحلول كلوريد الصوديوم بتركيز 9 ملغم / مل (0 .9٪) للحقن قبل إعطائه .</p><p dir="RTL">سوف تتناول دائما اليكس حقن عن طريق الحقن في أحد الأوردة . وسيستمر التسريب الوريدي حوالي 10 دقائق .</p><p dir="RTL">تناول اليكس حقن مع سيسبلاتين:</p><p dir="RTL">سيعمل الطبيب أو صيدلي المستشفى على تحديد الجرعة التي تحتاجها بناءً على طولك ووزنك . يتم إعطاء سيسبلاتين أيضا عن طريق الحقن في أحد الأوردة ، ويتم إعطاؤه بعد 30 دقيقة تقريبًا من انتهاء الحقن باليكس. وسيستمر ضخ سيسبلاتين حوالي ساعتين .</p><p dir="RTL">عادةً يجب أن تتلقى التسريب الوريدي مرة واحدة كل 3 أسابيع .</p><p dir="RTL">الأدوية الإضافية:</p><p dir="RTL">الستيرويدات&nbsp;القشرية: سيصف لك طبيبك أقراص تحتوي على الستيرويدات&nbsp;القشرية (تعادل 4 ملغم من ديكساميثازون مرتين في اليوم) والتي ستحتاج إلى تناولها في اليوم السابق ، وفي اليوم التالي ، وبعد يوم من العلاج بتناول اليكس حقن . يتم إعطاؤك هذا الدواء لتقليل معدلات وشدة تفاعلات الجلد (حساسية الجلد) التي قد تواجهها أثناء علاجك بالأدوية المضادة للسرطان .</p><p dir="RTL">مكملات الفيتامينات: سيصف لك طبيبك حمض الفوليك يتم تناولها عن طريق الفم (فيتامين) أو الفيتامينات &nbsp;التي تحتوي على حامض الفوليك (350 إلى 1000 ميكروغرام) الذي يجب أن تتناوله مرة واحدة في اليوم بينما تتناول اليكس حقن . يجب تناول 5 جرعات على الأقل خلال السبعة أيام قبل تناول الجرعة الأولى من اليكس حقن . يجب أن تستمر في تناول حمض الفوليك لمدة 21 يومًا بعد آخر جرعة تتناولها من اليكس حقن ستحصل أيضًا على حقنة من فيتامين B12 (1000 ميكروغرام) قبل أسبوع من تناول اليكس حقن ثم كل 9 أسابيع تقريبًا (ما يعادل 3 كورسات علاجية باليكس حقن) . يتم إعطاء فيتامين ب 12 وحمض الفوليك لك لتقليل التأثيرات السامة المحتملة للأدوية المضادة للسرطان .</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من أنها لا تؤثر في الجميع . يجب عليك الاتصال بالطبيب على الفور إذا لاحظت أيًا مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى أو عدوى (شائعة): إذا كان لديك درجة حرارة 38 درجة مئوية أو أكثر ، أو التعرق أو علامات أخرى من العدوى (حيث قد يكون لديك نقص في خلايا الدم البيضاء لأقل من المعتاد وهو أمر شائع جدا) . قد تكون هناك عدوى شديدة (تعفن الدم) ويمكن أن تؤدي إلى الوفاة .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا بدأت الشعور بألم في الصدر (شائع) أو لديك سرعة معدل ضربات قلب (غير شائع) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك ألم أو احمرار أو تورم أو تقرحات في الفم (شائع جدا) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي: إذا كنت مصاب بالطفح الجلدي (شائع جداً) / حرقان أو إحساس بالوخذ (شائع) أو حمى (شائعة) . نادرًا ما تكون تفاعلات شديدة بحساسية الجلد ويمكن أن تؤدي إلى الوفاة .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بطبيبك إذا كنت تعاني من طفح جلدي حاد ، أو حكة ، أو تقرحات (متلازمة ستيفنز جونسون أو انحلال البشرة النخري السمي) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت بالتعب ، أو الشعور بالإغماء ، أو أن تصاب بضيق في التنفس ، أو إذا بدت بالشحوب (حيث قد يكون لديك نقص في الهيموجلوبين أقل من المعتاد وهو أمر شائع جدا) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من النزيف في اللثة أو الأنف أو الفم أو أي نزيف لا يتوقف ، أو تمرير بول باللون الأحمرأو الوردي ، كدمات غير متوقعة (حيث قد يكون لديك نقص في الصفيحات أقل من الطبيعي وهو أمر شائع جدًا) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ضيق مفاجئ في التنفس ، أو ألم شديد في الصدر أو سعال مع البلغم الدموي (غير شائع) (قد يشير إلى تجلط الدم في الأوعية الدموية للرئتين) .</p><p dir="RTL">قد تشمل الآثار الجانبية لاليكس حقن:</p><p dir="RTL"><strong>شائع جدا (قد يؤثر على أكثر من شخص من كل 10 أشخاص)</strong></p><p dir="RTL">انخفاض خلايا الدم البيضاء</p><p dir="RTL">انخفاض مستوى الهيموجلوبين (فقر الدم) انخفاض عدد الصفائح الدموية</p><p dir="RTL">الإسهال والقيء</p><p dir="RTL">ألم واحمرار وتورم أو تقرحات في فمك والغثيان</p><p dir="RTL">فقدان الشهية التعب (الإرهاق) طفح جلدي</p><p dir="RTL">فقدان الشعر الإمساك فقدان الإحساس</p><p dir="RTL">الكلى: نتائج اختبارات الدم غير طبيعية</p><p dir="RTL"><strong>شائع (قد يؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">رد فعل تحسسي: طفح جلدي / حرقان أو إحساس بالوخذ</p><p dir="RTL">العدوى بما في ذلك تعفن الدم</p><p dir="RTL">حمة</p><p dir="RTL">جفاف</p><p dir="RTL">فشل كلوي</p><p dir="RTL">تهيج الجلد والحكة</p><p dir="RTL">ألم في الصدر</p><p dir="RTL">ضعف العضلات</p><p dir="RTL">التهاب الملتحمة (العين الملتهبة)</p><p dir="RTL">معده مضطربه</p><p dir="RTL">ألم في البطن</p><p dir="RTL">تغيير الذوق</p><p dir="RTL">الكبد: نتائج اختبارات الدم غير طبيعية</p><p dir="RTL">عيون دامعة</p><p dir="RTL"><strong>غير شائع (قد يؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص)</strong></p><p dir="RTL">فشل كلوي حاد</p><p dir="RTL">سرعة في معدل ضربات القلب</p><p dir="RTL">وقد لوحظ التهاب بطانة المريء مع العلاج باليكس حقن/ العلاج الإشعاعي .</p><p dir="RTL">التهاب القولون (التهاب بطانة الأمعاء الغليظة ، والذي قد يصاحبه نزيف معوي أو مستقيمي)</p><p dir="RTL">الالتهاب الرئوي الخلالي (تندب الأكياس الهوائية في الرئة)</p><p dir="RTL">الوذمة (السوائل الزائدة في أنسجة الجسم ، مما يؤدي إلى التورم) يعاني بعض المرضى من نوبة قلبية أو سكتة دماغية أو &quot;سكتة صغيرة&quot; أثناء تناول اليكس حقن عادةً مع علاج آخر بمضاد للسرطان .</p><p dir="RTL">قلة الكريات الشاملة - مزيج بين انخفاضات في الخلايا البيضاء والخلايا الحمراء والصفائح الدموية .</p><p dir="RTL">قد يحدث الالتهاب الرئوي الإشعاعي (تندب الأكياس الهوائية للرئة المرتبطة بالعلاج الإشعاعي) في المرضى الذين يعالجون أيضًا بالإشعاع قبل أو أثناء أو بعد العلاج بتناول اليكس حقن .</p><p dir="RTL">وقد تم الإبلاغ عن الألم الحاد ، ودرجة الحرارة المنخفضة وتغير اللون .</p><p dir="RTL">جلطات الدم في الأوعية الدموية الرئوية (انسداد رئوي) .</p><p dir="RTL"><strong>نادر (قد يؤثر على ما يصل إلى شخص من كل 1000 شخص)</strong></p><p dir="RTL">&nbsp;المعاودة&nbsp;الإشعاعية (طفح جلدي مثل حروق الشمس الحادة) الذي يمكن أن يحدث على الجلد الذي سبق أن تعرض للعلاج الإشعاعي ، من أيام إلى سنوات بعد الإشعاع .</p><p dir="RTL">الحالات الفقاعية (أمراض الجلد المتقرحة) ، بما في ذلك متلازمة ستيفنز جونسون وانحلال البشرة النخري السمي .</p><p dir="RTL">فقر الدم الانحلالي بوساطة المناعة (تدمير لخلايا الدم الحمراء بوساطة الأجسام المضادة) .</p><p dir="RTL">التهاب الكبد</p><p dir="RTL">صدمة حساسية (رد فعل تحسسي شديد) .</p><p dir="RTL"><strong>غير معروف: لا يمكن تقدير معدلاتها من البيانات المتاحة</strong></p><p dir="RTL">تورم الطرف السفلي مع الألم واحمرار</p><p dir="RTL">زيادة انتاج البول</p><p dir="RTL">العطش وزيادة استهلاك المياه</p><p dir="RTL">فرط صوديوم الدم - زيادة الصوديوم في الدم</p><p dir="RTL">إذا كان لديك أي من هذه الأعراض و / أو الحالات . يجب عليك إخبار طبيبك في أقرب وقت ممكن عندما تبدأ في مواجهة أي من هذه الآثار الجانبية .</p><p dir="RTL">إذا كنت قلقًا بشأن أي آثار جانبية ، تحدث إلى طبيبك .</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية ، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة ، يرجى إبلاغ الطبيب المعالج أو الصيدلي . وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة . يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه) . بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء .</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:569px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222&nbsp;&nbsp; ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp;يرجى الاتصال بالسلطة الصحية المختصة .</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30&deg; مئوية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بالتخزين في العبوة الأصلية من أجل الحماية من الرطوبة .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم اليكس حقن بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية . يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر .</p><p dir="RTL"><strong>بعد الحل (الإذابة):</strong></p><p dir="RTL">إعادة الحل وتحضير محلول التسريب الوريدي: يجب استخدام المنتج على الفور . عندما يتم التحضير حسب التوجيهات ، تم التحقق من الثبات الكيميائي والفيزيائي لمحلول اليكس الذي تم إعادة حله لتحضير محلول التسريب الوريدي وذلك لمدة 24 ساعة عند درجة الحرارة المبردة .</p><p dir="RTL">هذا الدواءمخصص للاستخدام لمرة واحدة فقط ؛ يجب التخلص من أي محلول غير مستخدم وفقا للمتطلبات المحلية .</p><p dir="RTL">لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية . اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة . هذه التدابير تساعد في الحفاظ على البيئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي بيمتريكسد ثنائي الصوديوم 2,5 هيدرات</p><p dir="RTL">حيث تحتوي كل قارورة على بيمتريكسد ثنائي الصوديوم 2,5 هيدرات ما يكافئ بيمتريكسد 500 ملغم .</p><p dir="RTL">الصواغات الاخرى: مانيتول (بيرليتول PF) ، هيدروكسيد الصوديوم ، حمض الهيدروكلوريك ، الماء للحقن وغاز النيتروجين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماهو الشكل الصيدلاني</strong><strong> </strong><strong>ل</strong><strong>اليكس </strong><strong>و وصفه وحجم عبوته</strong></p><p dir="RTL">مسحوق مجفف بالتجميد على شكل عجينة ذات لون أبيض إلى اللون الأصفر الفاتح أو الأخضر المائل للإصفرار .</p><p dir="RTL"><strong>توافر</strong><strong> </strong><strong>اليكس </strong><strong>حقن</strong></p><p dir="RTL">قارورة زجاجية .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق:</strong></p><p dir="RTL">شركة أماروكس السعودية للصناعة<br />شارع الجامعة &ndash; الملز &ndash; الرياض 11441<br />المملكة العربية السعودية .</p><p dir="RTL">تليفون: + 966 114772215</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            9/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alix for injection 500mg/vial 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains Pemetrexed Disodium 2.5 Hydrate equivalent to Pemetrexed 500 mg, 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alix Injection 500mg/vial 
White to Either light yellow or green-yellow lyophilized cake. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>indications</strong> Malignant pleural mesothelioma</p><p>Alix injection in combination with cisplatin is indicated for the treatment of chemotherapy na&iuml;ve patients with unresectable malignant pleural mesothelioma.</p><p>Non-small cell lung cancer</p><p>Alix injection in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).</p><p>Alix injection is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1).</p><p>Alix injection is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alix injection must only be administered under the supervision of a physician qualified in the use of anti-cancer<strong> </strong>chemotherapy.<strong> </strong></p><p>Alix injection in combination with cisplatin</p><p>The recommended dose of Pemetrexed injection is 500 mg/m2 of body surface area (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m<sup>2</sup> BSA infused over two hours approximately 30 minutes after completion of the pemetrexed infusion on the first day of each 21-day cycle. Patients must receive adequate anti-emetic treatment and appropriate hydration prior to and/or after receiving cisplatin (see also cisplatin Summary of Product Characteristics for specific dosing advice).</p><p>Alix injection as single agent</p><p>In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of Pemetrexed injection is 500 mg/m<sup>2</sup> BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.</p><p>Pre-medication regimen</p><p>To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration. The corticosteroid should be equivalent to 4 mg of dexamethasone administered orally twice a day (see section 4.4).</p><p>To reduce toxicity, patients treated with pemetrexed must also receive vitamin supplementation (see section 4.4).</p><p>Patients must take oral folic acid or a multivitamin containing folic acid (350 to 1000 micrograms) on a daily basis. At least five doses of folic acid must be taken during the seven days preceding the first dose of pemetrexed, and dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed. Patients must also receive an intramuscular injection of vitamin B12 (1000 micrograms) in the week preceding the first dose of pemetrexed and once every three cycles thereafter. Subsequent vitamin B12 injections may be given on the same day as pemetrexed.</p><p>Monitoring</p><p>Patients receiving pemetrexed should be monitored before each dose with a complete blood count, including a differential white cell count (WCC) and platelet count. Prior to each chemotherapy administration blood chemistry tests should be collected to evaluate renal and hepatic function. Before the start of any cycle of chemotherapy, patients are required to have the following: absolute neutrophil count (ANC) should be &ge; 1500 cells/mm3 and platelets should be &ge; 100,000 cells/mm3.</p><p>Creatinine clearance should be &ge; 45 ml/min.</p><p>The total bilirubin should be &le; 1.5 times upper limit of normal. Alkaline phosphatase (AP), aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) should be &le; 3 times upper limit of normal. Alkaline phosphatase, AST and ALT &le; 5 times upper limit of normal is acceptable if liver has tumour involvement.</p><p>Dose adjustments</p><p>Dose adjustments at the start of a subsequent cycle should be based on nadir haematologic counts or maximum nonhaematologic toxicity from the preceding cycle of therapy. Treatment may be delayed to allow sufficient time for recovery. Upon recovery patients should be retreated using the guidelines in Tables 1, 2 and 3, which are applicable for Pemetrexed Injection used as a single agent or in combination with cisplatin</p><table border="0" cellspacing="0" cellpadding="0" style="width:659px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 1. Dose Modification Table for Pemetrexed injection (as Single Agent or in </strong></p><p><strong>Combination) and Cisplatin - Haematologic Toxicities </strong></p></td></tr><tr><td style="vertical-align:top"><p>Nadir ANC &lt; 500 /mm<sup>3</sup> and nadir platelets &ge;</p><p>50,000 /mm<sup>3</sup>&nbsp;</p></td><td style="vertical-align:top"><p>75% of previous dose (both Pemetrexed</p><p>injection and cisplatin)<strong> </strong></p></td></tr><tr><td style="vertical-align:bottom"><p>3</p><p>Nadir platelets &lt; 50,000/mm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; regardless of nadir</p><p>ANC<strong> </strong></p></td><td style="vertical-align:top"><p>75% of previous dose (both Pemetrexed</p><p>injection and cisplatin)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a</p><p>Nadir platelets &lt; 50,000/mm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with bleeding ,</p><p>regardless</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>50% of previous dose (both Pemetrexed injection and cisplatin)</p></td></tr></tbody></table><p>a</p><p>These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI</p><p>1998) definition</p><p>&nbsp;</p><p>of &ge; CTC Grade 2 bleeding.</p><p>If patients develop non-haematologic toxicities &ge; Grade 3 (excluding neurotoxicity), Pemetrexed Injection should be withheld until resolution to less than or equal to the patient&#39;s pre-therapy value.</p><p>Treatment should be resumed according to the guidelines in Table 2.</p><table border="0" cellspacing="0" cellpadding="0" style="width:740px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 2. Dose Modification Table for Pemetrexed injection (as Single Agent or in Combination) and </strong></p><p><strong>Cisplatin - Non- Haematologic Toxicities </strong><sup>a, b</sup><strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dose of Pemetrexed (mg/m<sup>2</sup>) </strong></p></td><td style="vertical-align:top"><p><strong>Dose for Cisplatin (mg/m<sup>2</sup>) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Any Grade 3 or 4 toxicities except mucositis</p></td><td style="vertical-align:top"><p>75% of previous dose</p></td><td><p>75% of previous dose</p></td></tr><tr><td style="vertical-align:top"><p>Any diarrhoea requiring hospitalisation (irrespective of grade) or Grade 3 or 4 diarrhoea</p></td><td style="vertical-align:top"><p>75% of previous dose</p></td><td style="vertical-align:top"><p>75% of previous dose</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3 or 4 mucositis</p></td><td style="vertical-align:top"><p>50% of previous dose</p></td><td style="vertical-align:bottom"><p>100% of previous dose</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a&nbsp; </sup>National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) <sup>&nbsp;b </sup>Excluding neurotoxicity</p></td></tr></tbody></table><p>&nbsp;</p><p>In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed injection and cisplatin is documented in Table 3. Patients should discontinue therapy if Grade 3 or 4 neurotoxicity is observed.</p><table border="0" cellspacing="0" cellpadding="0" style="width:740px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 3. Dose Modification Table for Pemetrexed injection (as Single Agent or in Combination) and </strong></p><p><strong>Cisplatin - Neurotoxicity </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>CTC<sup> a</sup> Grade </strong></p></td><td style="vertical-align:top"><p><strong>Dose of pemetrexed (mg/m<sup>2</sup>) </strong></p></td><td style="vertical-align:top"><p><strong>Dose for Cisplatin (mg/m<sup>2</sup>) </strong></p></td></tr><tr><td style="vertical-align:top"><p>0-1</p></td><td style="vertical-align:top"><p>100% of previous dose</p></td><td style="vertical-align:bottom"><p>100% of previous dose</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>100% of previous dose</p></td><td style="vertical-align:top"><p>50% of previous dose</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a&nbsp; </sup>National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998)</p></td></tr></tbody></table><p>Treatment with Pemetrexed injection should be discontinued if a patient experiences any haematologic or non- haematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.</p><p><u>Special populations</u> <u>Elderly:</u>&nbsp;</p><p>In clinical studies, there has been no indication that patients 65 years of age or older are at increased risk of adverse reaction compared to patients younger than 65 years old. No dose reductions other than those recommended for all patients are necessary.</p><p>Paediatric population</p><p>There is no relevant use of Pemetrexed injection in the paediatric population in malignant pleural mesothelioma and non-small cell lung cancer.</p><p>Patients with renal impairment<em> </em>(standard Cockcroft and gault formula or glomerular filtration rate measured Tc99m-DPTA serum clearance method)</p><p>Pemetrexed is primarily eliminated unchanged by renal excretion. In clinical studies, patients with creatinine clearance of &ge; 45 ml/min required no dose adjustments other than those recommended for all patients. There are insufficient data on the use of pemetrexed in patients with creatinine clearance below 45 ml/min; therefore the use of Pemetrexed is not recommended (see section 4.4).</p><p>Patients with hepatic impairment</p><p>No relationships between AST (SGOT), ALT (SGPT), or total bilirubin and pemetrexed pharmacokinetics were identified. However patients with hepatic impairment such as bilirubin &gt; 1.5 times the upper limit of normal and/or aminotransferase &gt; 3.0 times the upper limit of normal (hepatic metastases absent) or &gt; 5.0 times the upper limit of normal (hepatic metastases present) have not been specifically studied.</p><p><strong><u>Method of administration:</u> </strong></p><p>Alix injection is for intravenous use. Alix injection should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.</p><p>For precautions to be taken before handling or administering Alix injection and for instructions on reconstitution and dilution of Alix injection before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.  
Breast-feeding (see section 4.6). 
Concomitant yellow fever vaccine (see section 4.5). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pemetrexed can suppress bone marrow function as manifested by neutropenia, thrombocytopenia and anaemia (or pancytopenia) (see section 4.8). Myelosuppression is usually the dose-limiting toxicity. Patients should be monitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count (ANC) returns to &ge; 1500 cells/mm3 and platelet count returns to &ge; 100,000 cells/mm3. Dose reductions for subsequent cycles are based on nadir ANC, platelet count and maximum non-haematologic toxicity seen from the previous cycle (see section 4.2).</p><p>Less toxicity and reduction in Grade 3/4 haematologic and non-haematologic toxicities such as neutropenia, febrile neutropenia and infection with Grade 3/4 neutropenia were reported when pretreatment with folic acid and vitamin B12 was administered. Therefore, all patients treated with pemetrexed must be instructed to take folic acid and vitamin B12 as a prophylactic measure to reduce treatment-related toxicity (see section 4.2).</p><p>Skin reactions have been reported in patients not pre-treated with a corticosteroid. Pre-treatment with dexamethasone (or equivalent) can reduce the incidence and severity of skin reactions (see section</p><p>4.2).</p><p>An insufficient number of patients has been studied with creatinine clearance of below 45 ml/min. Therefore, the use of pemetrexed in patients with creatinine clearance of &lt; 45 ml/min is not recommended (see section 4.2).</p><p>Patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min) should avoid taking nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, and acetylsalicylic acid (&gt; 1.3 g daily) for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.5).</p><p>In patients with mild to moderate renal insufficiency eligible for pemetrexed therapy NSAIDs with long elimination halflives should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following Pemetrexed administration (see section 4.5).</p><p>Serious renal events, including acute renal failure, have been reported with pemetrexed alone or in association with other chemotherapeutic agents. Many of the patients in whom these occurred had underlying risk factors for the development of renal events including dehydration or pre-existing hypertension or diabetes. Nephrogenic diabetes insipidus and renal tubular necrosis were also reported in post marketing setting with pemetrexed alone or with other chemotherapeutic agents. Most of these events resolved after pemetrexed withdrawal. Patients should be regularly monitored for acute tubular necrosis, decreased renal function and signs and symptoms of nephrogenic diabetes insipidus (e.g. hypernatraemia).</p><p>The effect of third space fluid, such as pleural effusion or ascites, on pemetrexed is not fully defined. A phase 2 study of pemetrexed in 31 solid tumour patients with stable third space fluid demonstrated no difference in pemetrexed dose normalized plasma concentrations or clearance compared to patients without third space fluid collections. Thus, drainage of third space fluid collection prior to pemetrexed treatment should be considered, but may not be necessary.</p><p>Due to the gastrointestinal toxicity of pemetrexed given in combination with cisplatin, severe dehydration has been observed. Therefore, patients should receive adequate antiemetic treatment and appropriate hydration prior to and/or after receiving treatment.</p><p>Serious cardiovascular events, including myocardial infarction and cerebrovascular events have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent. Most of the patients in whom these events have been observed had preexisting cardiovascular risk factors (see section 4.8).</p><p>Immunodepressed status is common in cancer patients. As a result, concomitant use of live attenuated vaccines is not recommended (see section 4.3 and 4.5).</p><p>Pemetrexed can have genetically damaging effects. Sexually mature males are advised not to father a child during the treatment and up to 6 months thereafter. Contraceptive measures or abstinence are recommended. Owing to the possibility of pemetrexed treatment causing irreversible infertility, men are advised to seek counselling on sperm storage before starting treatment.</p><p>Women of childbearing potential must use effective contraception during treatment with pemetrexed (see section 4.6).</p><p>Cases of radiation pneumonitis have been reported in patients treated with radiation either prior, during or subsequent to their pemetrexed therapy. Particular attention should be paid to these patients and caution exercised with use of other radiosensitising agents.Cases of radiation recall have been reported in patients who received radiotherapy weeks or years previously.</p><p>Excipients Alix Injection 100 mg powder for concentrate for solution for infusion</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &#39;sodium- free&#39;.</p><p>Pemetrexed Injection 500 mg powder for concentrate for solution for infusion</p><p>This medicinal product contains 54 mg sodium per vial, equivalent to 2.7 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pemetrexed is mainly eliminated unchanged renally by tubular secretion and to a lesser extent by glomerular filtration. Concomitant administration of nephrotoxic drugs (e.g. aminoglycoside, loop diuretics, platinum compounds, cyclosporin) could potentially result in delayed clearance of pemetrexed. This combination should be used with caution. If necessary, creatinine clearance should be closely monitored.</p><p>Concomitant administration of substances that are also tubularly secreted (e.g. probenecid, penicillin) could potentially result in delayed clearance of pemetrexed. Caution should be made when these drugs are combined with pemetrexed. If necessary, creatinine clearance should be closely monitored. In patients with normal renal function (creatinine clearance &ge; 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen &gt; 1600 mg/day) and acetylsalicylic acid at higher dose (&ge; 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse reactions.</p><p>Therefore, caution should be made when administering higher doses of NSAIDs or acetylsalicylic acid, concurrently with pemetrexed to patients with normal function (creatinine clearance &ge; 80 ml/min).</p><p>In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g. ibuprofen) or acetylsalicylic acid at higher dose should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).</p><p>In the absence of data regarding potential interaction with NSAIDs having longer half-lives such as piroxicam or rofecoxib, the concomitant administration with pemetrexed in patients with mild to moderate renal insufficiency should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section 4.4). If concomitant administration of NSAIDs is necessary, patients should be monitored closely for toxicity, especially myelosuppression and gastrointestinal toxicity.</p><p>Pemetrexed undergoes limited hepatic metabolism. Results from <em>in vitro </em>studies with human liver microsomes indicated that pemetrexed would not be predicted to cause clinically significant inhibition of the metabolic clearance of drugs metabolised by CYP3A, CYP2D6, CYP2C9, and CYP1A2.</p><p>Interactions common to all cytotoxics</p><p>Due to the increased thrombotic risk in patients with cancer, the use of anticoagulation treatment is frequent. The high intra-individual variability of the coagulation status during diseases and the possibility of interaction between oral anticoagulants and anticancer chemotherapy require increased frequency of INR (International Normalised Ratio) monitoring, if it is decided to treat the patient with oral anticoagulants.</p><p>Concomitant use contraindicated: Yellow fever vaccine: risk of fatal generalised vaccinale disease (see section 4.3).</p><p>Concomitant use not recommended: Live attenuated vaccines (except yellow fever, for which concomitant use is contraindicated): risk of systemic, possibly fatal, disease. The risk is increased in subjects who are already immunosuppressed by their underlying disease. Use an inactivated vaccine where it exists (poliomyelitis) (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential / Contraception in males and females</p><p>Women of childbearing potential must use effective contraception during treatment with Pemetrexed. Pemetrexed can have genetically damaging effects. Sexually mature males are advised not to father a child during the treatment and up to 6 months thereafter. Contraceptive measures or abstinence are recommended.</p><p><u>Pregnancy</u></p><p>There are no data from the use of pemetrexed in pregnant women but pemetrexed, like other antimetabolites, is suspected to cause serious birth defects when administered during pregnancy. Animal studies have shown reproductive toxicity (see section 5.3). Pemetrexed should not be used during pregnancy unless clearly necessary,after a careful consideration of the needs of the mother and the risk for the foetus (see section 4.4).</p><p><u>Breast-feeding</u></p><p>It is unknown whether pemetrexed is excreted in human milk and adverse reactions on the breastfeeding child cannot be excluded. Breast-feeding must be discontinued during pemetrexed therapy (see section 4.3)<em>.</em></p><p><u>Fertility</u></p><p>Owing to the possibility of pemetrexed treatment causing irreversible infertility, men are advised to seek counselling on sperm storage before starting treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, it has been reported that pemetrexed may cause fatigue. Therefore patients should be cautioned against driving or operating machines if this event occurs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p>The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis. Other undesirable effects include renal toxicities, increased aminotransferases, alopecia, fatigue, dehydration, rash, infection/sepsis and neuropathy. Rarely seen events include Stevens-Johnson syndrome and toxic epidermal necrolysis.</p><p>Tabulated list of adverse reactions</p><p>The table 4 lists the adverse drug events regardless of causality associated with pemetrexed used either as a monotherapy treatment or in combination with cisplatin from the pivotal registration studies (JMCH, JMEI, JMBD,JMEN and PARAMOUNT) and from the post marketing period.</p><p>ADRs are listed by MedDRA body system organ class. The following convention has been used for classification of frequency: very common: &ge; 1/10; common: &ge; 1/100 to &lt; 1/10; uncommon: &ge; 1/1,000 to &lt; 1/100; rare: &ge; 1/10,000 to &lt; 1/1,000; very rare: &lt; 1/10,000) and not known (cannot be estimated from the available data).</p><p>Table 4. Frequencies of all grades adverse drug events regardless of causality from the pivotal registration studies: JMEI (ALIMTA vs Docetaxel), JMDB (ALIMTA and Cisplatin versus GEMZAR and Cisplatin, JMCH (ALIMTA plus Cisplatin versus Cisplatin), JMEN and</p><p><strong>PARAMOUNT (Pemetrexed plus Best Supportive Care versus Placebo plus Best Supportive Care) and from post-marketing period. </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System </strong></p><p><strong>Organ Class </strong>&nbsp;</p><p><strong>(MedDRA)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Very common</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Common</strong>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Uncommon</strong>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Rare</strong>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Very rare</strong>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Not known</strong>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Infection<sup>a</sup></p><p>Pharyngitis</p></td><td style="vertical-align:top"><p>Sepsis<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dermo-</p><p>hypodermitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;&nbsp; &nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:bottom"><p>Neutropenia</p><p>Leukopenia Haemoglobin</p><p>decreased</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Febrile neutropenia Platelet count decreased</p></td><td style="vertical-align:bottom"><p>Pancytopenia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Autoimmune haemolytic anaemia</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune System disorders</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Anaphylactic shock</p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Taste disorder Peripheral motor neuropathy Peripheral sensory neuropathy Dizziness</p></td><td style="vertical-align:bottom"><p>Cerebrovascular accident</p><p>Ischaemic stroke Haemorrhage</p><p>intracranial&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Conjunctivitis</p><p>Dry eye Lacrimation increased</p><p>Keratoconjunctivitis</p><p>sicca</p><p>Eyelid oedema Ocular surface disease</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Cardiac failure</p><p>Arrhythmia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angina Myocardial infarction&nbsp; Coronary artery disease Arrhythmia supraventricular</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peripheral ischaemia<sup>c</sup></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary embolism&nbsp;</p><p>Interstitial pneumonitis<sup>bd</sup></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Stomatitis</p><p>Anorexia</p><p>Vomiting</p></td><td style="vertical-align:top"><p>Dyspepsia</p><p>Constipation</p><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Rectal haemorrhage</p><p>Gastrointestinal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Diarrhoea</p><p>Nausea</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>haemorrhage</p><p>Intestinal perforation</p><p>Oesophagitis</p><p>Colitis <sup>e</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased Aspartate aminotransferase increased</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>Rash Skin exfoliation&nbsp;</p></td><td style="vertical-align:top"><p>Hyperpigmentation</p><p>Pruritus Erythema multiforme Alopecia</p><p>Urticaria</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Erythema</p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>StevensJohnson syndrome<sup>b</sup> Toxic epidermal</p><p>necrolysis<sup>b</sup> Pemphigoid Dermatitis bullous Acquired epidermolysis bullosa Erythematous oedema<sup>f</sup>&nbsp; Pseudocellu-</p><p>litis</p><p>Dermatitis</p><p>Eczema</p><p>Prurigo</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Creatinine clearance decreased Blood creatinine increased<sup>e</sup></p></td><td style="vertical-align:top"><p>Renal failure Glomerular</p><p>filtration rate decreased</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Nephroge-</p><p>nic diabetes insipidus Renal tubular</p><p>necrosis</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and</p><p>administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Pyrexia</p><p>Pain</p><p>Oedema</p><p>Chest pain Mucosal inflammation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Gamma-</p><p>glutamyltransferase</p><p>increased</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Radiation oesophagitis Radiation pneumonitis</p></td><td style="vertical-align:top"><p>Recall phenomenon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup> with and without neutropenia&nbsp; <sup>b</sup> in some cases fatal&nbsp; <sup>c</sup> sometimes leading to extremity necrosis&nbsp; <sup>d</sup> with respiratory insufficiency <sup>e</sup>seen only in combination with cisplatin&nbsp; <sup>f</sup> mainly of the lower limbs</p><p><u><strong>Reporting of suspected adverse reactions&nbsp;</strong></u></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects&nbsp;&nbsp;&nbsp; not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em>Saudi Arabia<em>:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:512px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong><em>o Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reported symptoms of overdose include neutropenia, anaemia, thrombocytopenia, mucositis, sensory polyneuropathy and rash. Anticipated complications of overdose include bone marrow suppression as manifested by neutropenia, thrombocytopenia and anaemia. In addition, infection with or without fever, diarrhoea, and/or mucositis may be seen. In the event of suspected overdose, patients should be monitored with blood counts and should receive supportive therapy as necessary. The use of calcium folinate / folinic acid in the management of pemetrexed overdose should be considered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Folic acid analogues. ATC code: L01BA04</p><p>&nbsp;injection is a multi-targeted anti-cancer antifolate agent that exerts its action by disrupting crucial folatedependent metabolic processes essential for cell replication.</p><p><em>In vitro </em>studies have shown that pemetrexed behaves as a multitargeted antifolate by inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are key folate-dependent enzymes for the <em>de novo </em>biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is rapidly and efficiently converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are even more potent inhibitors of TS and GARFT.Polyglutamation is a time- and concentration-dependent process that occurs in tumour cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Pemetrexed injection in all subsets of the paediatric population in the granted indications (see Section</p><p>4.2).</p><p>Clinical efficacy</p><p><em>Mesothelioma </em></p><p>EMPHACIS, a multicentre, randomised, single-blind phase 3 study of Pemetrexed injection plus cisplatin versus cisplatin in chemonaive patients with malignant pleural mesothelioma, has shown that patients treated with ALIMTA and cisplatin had a clinically meaningful 2.8-month median survival advantage over patients receiving cisplatin alone.</p><p>During the study, low-dose folic acid and vitamin B12 supplementation was introduced to patients&#39; therapy to reduce toxicity. The primary analysis of this study was performed on the population of all patients randomly assigned to a treatment arm who received study drug (randomised and treated). A subgroup analysis was performed on patients who received folic acid and vitamin B12 supplementation during the entire course of study therapy (fully supplemented). The results of these analyses of efficacy are summarised in the table below:</p><p>Efficacy of Pemetrexed injection plus cisplatin vs. cisplatin in malignant pleural mesothelioma</p><table border="0" cellspacing="0" cellpadding="0" style="width:715px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Randomised and treated patients</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Fully supplemented patients</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Efficacy parameter</strong></p></td><td style="vertical-align:top"><p><strong>Pemetre xed </strong></p><p><strong>injection </strong></p><p><strong>/ </strong></p></td><td style="vertical-align:top"><p><strong>Cisplati n (N = 222)</strong></p></td><td style="vertical-align:top"><p><strong>Pemetrexed </strong></p><p><strong>injection / </strong></p><p><strong>Cisplatin (N </strong></p><p><strong>= 168)</strong></p></td><td style="vertical-align:top"><p><strong>Cisplatin (N = 163)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median overall survival</p><p>(months)</p></td><td style="vertical-align:top"><p>1</p><p>2</p><p>.</p></td><td style="vertical-align:top"><p>9.</p><p>3</p></td><td style="vertical-align:top"><p>13.3</p></td><td style="vertical-align:top"><p>10.0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>(10.0-14.4)</p></td><td style="vertical-align:top"><p>(7.8-10.7)</p></td><td style="vertical-align:top"><p>(11.4-14.9)</p></td><td style="vertical-align:top"><p>(8.4-11.9)</p></td></tr><tr><td style="vertical-align:top"><p>Log rank <em>p</em>-value*</p></td><td colspan="2" style="vertical-align:bottom"><p>0.</p><p>0</p></td><td colspan="2" style="vertical-align:top"><p>0.051</p></td></tr><tr><td style="vertical-align:bottom"><p>Median time to tumour progression (months)</p></td><td style="vertical-align:top"><p>5</p><p>.</p></td><td style="vertical-align:top"><p>3.</p><p>9</p></td><td style="vertical-align:top"><p>6.1</p></td><td style="vertical-align:top"><p>3.9</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>7</p><p>(4.9-6.5)</p></td><td style="vertical-align:top"><p>(2.8-4.4)</p></td><td style="vertical-align:top"><p>(5.3-7.0)</p></td><td style="vertical-align:top"><p>(2.8-4.5)</p></td></tr><tr><td style="vertical-align:top"><p>Log rank <em>p</em>-value*</p></td><td colspan="2" style="vertical-align:top"><p>0.</p></td><td colspan="2" style="vertical-align:top"><p>0.008</p></td></tr><tr><td style="vertical-align:top"><p>Time to treatment failure</p><p>(months)</p></td><td style="vertical-align:top"><p>4</p><p>.</p><p>5</p></td><td style="vertical-align:top"><p>2.</p><p>7</p></td><td style="vertical-align:top"><p>4.7</p></td><td style="vertical-align:top"><p>2.7</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>(3.9-4.9)</p></td><td style="vertical-align:top"><p>(2.1-2.9)</p></td><td style="vertical-align:top"><p>(4.3-5.6)</p></td><td style="vertical-align:top"><p>(2.2-3.1)</p></td></tr><tr><td style="vertical-align:bottom"><p>Log rank <em>p</em>-value*</p></td><td colspan="2" style="vertical-align:bottom"><p>0.</p></td><td colspan="2" style="vertical-align:bottom"><p>0.001</p></td></tr><tr><td style="vertical-align:top"><p>Overall response rate**</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>16.7%</p></td><td style="vertical-align:top"><p>45.5%</p></td><td style="vertical-align:top"><p>19.6%</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>.3</p><p>(34.8-48.1)</p></td><td style="vertical-align:top"><p>(12.0-22.2)</p></td><td style="vertical-align:top"><p>(37.8-53.4)</p></td><td style="vertical-align:top"><p>(13.8-26.6)</p></td></tr><tr><td style="vertical-align:top"><p>Fisher&#39;s exact <em>p</em>-value*</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>0. Abbreviation: CI = confidence interval.</p><p>*p-value refers to comparison between arms.</p><p>**In the Pemetrexed injection/cisplatin arm, randomised and treated (N=225) and fully supplemented (N=167).</p></td></tr></tbody></table><p>A statistically significant improvement of the clinically relevant symptoms (pain and dyspnoea) associated with malignant pleural mesothelioma in the Pemetrexed injection/cisplatin arm (212 patients) versus the cisplatin arm alone (218 patients) was demonstrated using the Lung Cancer Symptom Scale. Statistically significant differences in pulmonary function tests were also observed. The separation between the treatment arms was achieved by improvement in lung function in the Pemetrexed injection/cisplatin arm and deterioration of lung function over time in the control arm.</p><p>There are limited data in patients with malignant pleural mesothelioma treated with</p><p>2</p><p>Pemetrexed Injection alone. Pemetrexed injection at a dose of 500mg/m was studied as a single agent in 64 chemonaive patients with malignant pleural mesothelioma. The overall response rate was 14.1%.</p><p>NSCLC, second-line treatment</p><p>&nbsp;</p><p>A multi-centre, randomised, open-label Phase 3 study of Pemetrexed Injection versus docetaxel in patients with locally advanced or metastatic NSCLC after prior chemotherapy has shown median survival times of 8.3 months for patients treated with Pemetrexed Injection (Intent-To-Treat [ITT] population N = 283) and 7.9 months for patients treated with docetaxel (ITT N = 288). Prior chemotherapy did not include Pemetrexed Injection. An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of Pemetrexed Injection versus docetaxel for other than predominantly squamous histologies (N = 399, 9.3 versus 8.0 months, adjusted hazard ratio (HR) = 0.78; 95% CI = 0.61-1.00, p = 0.047) and was in favour of docetaxel for squamous cell carcinoma histology (N =172, 6.2 versus 7.4 months, adjusted HR = 1.56; 95% CI = 1.08-2.26, p = 0.018). There were no clinically relevant differences observed for the safety profile of PEMETREXED INJECTION within the histology subgroups.</p><p>Limited clinical data from a separate randomised, Phase 3, controlled trial, suggest that efficacy data (overall survival, progression-free survival) for Pemetrexed are similar between patients previously pre-treated with docetaxel (N = 41) and patients who did not receive previous docetaxel treatment (N = 540).</p><p><strong>Efficacy of Pemetrexed injection vs. Docetaxel in NSCLC - ITT population </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:738px"><tbody><tr><td colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Pemetrexed injection</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Docetaxel</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Survival time (months)</strong></p><p>&bull;&nbsp; Median (m)&nbsp;</p><p>&bull;&nbsp; 95% CI for median</p><p>&nbsp;</p></td><td><p>(N = 283)</p><p>8.3</p><p>(7.0-9.4)</p></td><td colspan="2"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (N = 288)</p><p>7.9</p><p>(6.3-9.2)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&bull;&nbsp; HR</p><p>&bull;&nbsp; 95% CI for HR</p><p>&bull;&nbsp; Non-inferiority <em>p</em>-value (HR)</p></td><td colspan="3"><p>0.99</p><p>&nbsp;</p><p>(0.82-1.20)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Progression free survival (months)</strong></p><p>&bull; Median</p></td><td style="vertical-align:bottom"><p>(n = 283)</p><p>&nbsp;2.9</p></td><td colspan="2" style="vertical-align:top"><p>(n = 288)&nbsp;</p><p>2.9</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&bull; HR (95% CI)<strong> </strong></p></td><td colspan="3" style="vertical-align:top"><p>0.97 (0.82-1.16)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Time to treatment failure (TTTF - months)</strong></p><p>&bull; Median</p><p>&nbsp;</p></td><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (n = 283)</p><p>2.3</p></td><td colspan="2"><p>(n = 288)</p><p>&nbsp;</p><p>2.1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>HR (95% CI)</p><p><strong>&nbsp;</strong></p></td><td colspan="3"><p>0.84 (0.71-0.997)</p></td></tr><tr><td colspan="2"><p><strong>Response </strong>(n: qualified for response)</p><p>&nbsp;</p><p>&bull;&nbsp; Response rate (%) (95% CI)</p><p>&nbsp;</p><p>&bull;&nbsp; Stable disease (%)</p></td><td><p>(N = 264)</p><p>9.1 (5.9-13.2)</p><p>45.8</p></td><td colspan="2"><p>(N = 274)</p><p>&nbsp;</p><p>8.8 (5.7-12.8)</p><p>&nbsp;</p><p>46.4</p></td></tr><tr><td colspan="5" style="vertical-align:bottom"><p>Abbreviations: CI = confidence interval; HR = hazard ratio; ITT = intent-to-treat; N = total population size</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>NSCLC, first-line treatment</p><p>A multi-centre, randomised, open-label, Phase 3 study of Pemetrexed injection plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC) showed that Pemetrexed injection plus cisplatin (Intent-To-Treat [ITT] population N = 862) met its primary endpoint and showed similar clinical efficacy as gemcitabine plus cisplatin (ITT N = 863) in overall survival (adjusted hazard ratio (HR) 0.94; 95% CI= 0.84-1.05). All patients included in this study had an ECOG performance status 0 or 1.</p><p>The primary efficacy analysis was based on the ITT population. Sensitivity analyses of main efficacy endpoints were also assessed on the Protocol Qualified (PQ) population. The efficacy analyses using PQ population are consistent with the analyses for the ITT population and support the non-inferiority of AC versus GC.&nbsp;</p><p>Progression-free survival (PFS) and overall response rate were similar between treatment arms: median PFS was&nbsp; 4.8&nbsp; months&nbsp; for pemetrexed&nbsp; injection&nbsp; plus&nbsp; cisplatin&nbsp; versus&nbsp; 5.1&nbsp; months&nbsp; for gemcitabine plus cisplatin (adjusted hazard ratio (HR) 1.04; 95% CI= 0.94-1.15), and overall response rate was 30.6% (95% CI= 27.3- 33.9) for Pemetrexed injection plus cisplatin versus 28.2% (95% CI= 25.0-31.4) for gemcitabine plus cisplatin. PFS data were partially confirmed by an independent review (400/1725 patients were randomly selected for review).</p><p>The analysis of the impact of NSCLC histology on overall survival demonstrated clinically relevant differences in survival according to histology, see table below.</p><p>Efficacy of Alix injection + cisplatin vs. gemcitabine + cisplatin in first-line non-small cell</p><p><strong>lung cancer &ndash; ITT population and histology subgroups</strong></p><table border="0" cellspacing="0" cellpadding="0" align="left" style="width:752px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><strong>ITT population and histology subgroups</strong></p></td><td colspan="4"><p><strong>Median overall survival in months </strong></p><p><strong>(95% CI)</strong></p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Adjusted hazard </strong></p><p><strong>ratio (HR) </strong></p><p><strong>(95% CI)</strong></p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Superiority <em>p</em>- value</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Pemetrexed injection + </strong></p><p><strong>Cisplatin</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Gemcitabin</strong></p><p><strong>e + </strong></p><p><strong>Cisplatin</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>ITT population</p><p>(N = 1725)</p></td><td style="vertical-align:top"><p>10.3</p><p>&nbsp;</p><p>(9.8 &ndash;</p><p>&nbsp;</p><p>11.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N = 862</p></td><td style="vertical-align:bottom"><p>10.3</p><p>&nbsp;</p><p>(9.6</p><p>&ndash;</p><p>&nbsp;</p><p>10</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N =</p><p>863</p></td><td style="vertical-align:top"><p>0.94<sup>a</sup><sub> </sub></p><p>&nbsp;</p><p>(0.84 &ndash;</p><p>&nbsp;</p><p>1.05)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>0.259</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Adenocarcinoma</p><p>(N = 847)</p></td><td style="vertical-align:top"><p>12.6</p><p>&nbsp;</p><p>(10.7 &ndash;</p><p>&nbsp;</p><p>13.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N = 436</p></td><td style="vertical-align:bottom"><p>10.9</p><p>&nbsp;</p><p>(10.</p><p>2 &ndash;</p><p>&nbsp;</p><p>11</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N =</p><p>411</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.84</p><p>&nbsp;</p><p>(0.71&ndash;0.99)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>0.033</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Large cell</p><p>(N = 153)</p></td><td style="vertical-align:top"><p>10.4</p><p>&nbsp;</p><p>(8.6 &ndash;</p><p>&nbsp;</p><p>14.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N = 76</p></td><td style="vertical-align:bottom"><p>6.7</p><p>&nbsp;</p><p>(5.5</p><p>&ndash;</p><p>&nbsp;</p><p>9.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N =</p><p>77</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.67</p><p>&nbsp;</p><p>(0.48&ndash;0.96)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>0.027</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Other</p><p>(N = 252)</p></td><td style="vertical-align:top"><p>8.6</p><p>&nbsp;</p><p>(6.8 &ndash;</p><p>&nbsp;</p><p>10.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N = 106</p></td><td style="vertical-align:bottom"><p>9.2</p><p>&nbsp;</p><p>(8.1</p><p>&ndash;</p><p>&nbsp;</p><p>10</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N =</p><p>146</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.08</p><p>&nbsp;</p><p>(0.81&ndash;1.45)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>0.586</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Squamous cell</p><p>(N = 473)</p></td><td style="vertical-align:top"><p>9.4</p><p>&nbsp;</p><p>(8.4 &ndash;</p><p>&nbsp;</p><p>10.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N = 244</p></td><td style="vertical-align:top"><p>10.8</p><p>&nbsp;</p><p>(9.5</p><p>&ndash;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N =</p><p>229</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.23</p><p>&nbsp;</p><p>(1.00&ndash;1.51)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>0.050</p></td></tr></tbody></table><p>12</p><table border="0" cellspacing="0" cellpadding="0" style="width:752px"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size.</p><p>&nbsp;</p><p>a</p><p>Statistically significant for non-inferiority, with the entire confidence interval for HR well below the 1.17645 non-inferiority margin (<em>p </em>&lt; 0.001).</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Kaplan-Meier plots of overall survival by histology </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_7000" o:spid="_x0000_i1027" type="#_x0000_t75"
 style='width:487.5pt;height:196.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="650" height="262" alt="" vspace="0" hspace="0" border="0" style="width:650px;height:262px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />&nbsp;</p><p>&nbsp;</p><p>There were no clinically relevant differences observed for the safety profile of pemetrexed injection plus cisplatin within the histology subgroups.</p><p>Patients treated with pemetrexed injection and cisplatin required fewer transfusions (16.4% versus 28.9%, p &lt; 0.001), red blood cell transfusions (16.1% versus 27.3%, p &lt; 0.001) and platelet transfusions (1.8% versus 4.5%, p = 0.002). Patients also required lower administration of erythropoietin/darbopoietin (10.4% versus 18.1%, p &lt; 0.001), G-CSF/GMCSF (3.1% versus 6.1%, p = 0.004), and iron preparations (4.3% versus 7.0%, p = 0.021). <u>NSCLC, maintenance treatment</u>&nbsp;</p><p>JMEN</p><p>A multi-centre, randomised, double-blind, placebo-controlled Phase 3 study (JMEN), compared the efficacy and safety of maintenance treatment with Alix injection plus best supportive care (BSC) (N = 441) with that of placebo plus BSC (N = 222) in patients with locally advanced (Stage IIIB) or metastatic (Stage IV) Non- Small Cell Lung Cancer (NSCLC) who did not progress after 4 cycles of first-line doublet therapy containing Cisplatin or Carboplatin in combination with Gemcitabine, Paclitaxel, or Docetaxel. First-line doublet therapy containing Pemetrexed injection was not included. All patients included in this study had an ECOG performance status 0 or 1. Patients received maintenance treatment until disease progression. Efficacy and safety were measured from the time of randomisation after completion of first-line (induction) therapy. Patients received a median of 5 cycles of maintenance treatment with Alix injection and 3.5 cycles of placebo. A total of 213 patients (48.3%) completed &ge; 6 cycles and a total of 103 patients (23.4%) completed &ge; 10 cycles of treatment with Pemetrexed injection.</p><p>The study met its primary endpoint and showed a statistically significant improvement in PFS in the pemetrexed injection arm over the placebo arm (N = 581, independently reviewed population; median of 4.0 months and 2.0 months, respectively) (hazard ratio = 0.60, 95% CI = 0.49-0.73, p &lt; 0.00001). The independent review of patient scans confirmed the findings of the investigator assessment of PFS. The median OS for the overall population (N = 663) was 13.4 months for the pemetrexed injection arm and 10.6 months for the placebo arm, hazard ratio = 0.79 (95% CI= 0.65-0.95, p = 0.01192).</p><p>Consistent with other pemetrexed injection studies, a difference in efficacy according to NSCLC histology was observed in JMEN. For patients with NSCLC other than predominantly squamous cell histology (N = 430, independently reviewed population) median PFS was 4.4 months for the Pemetrexed injection arm and 1.8 months for the placebo arm, hazard ratio = 0.47 (95% CI = 0.37-0.60, p = 0.00001). The median OS for patients with NSCLC other than predominantly squamous cell histology (N = 481) was 15.5 months for the Pemetrexed injection arm and 10.3 months for the placebo arm, hazard ratio = 0.70 (95% CI = 0.56-0.88, p = 0.002). Including the induction phase, the median OS for patients with NSCLC other than predominantly squamous cell histology was 18.6 months for the pemetrexed injection arm and</p><p>13.6 months for the placebo arm, hazard ratio= 0.71 (95% CI = 0.50.88, p = 0.002).</p><p>The PFS and OS results in patients with squamous cell histology suggested no advantage for Pemetrexed injection over placebo.</p><p>There were no clinically relevant differences observed for the safety profile of pemetrexed injection within the histology subgroups.</p><p><strong>JMEN: Kaplan-Meier plots of progression-free survival (PFS) and overall survival Pemetrexed injection versus placebo in patients with NSCLC other than predominantly squamous cell histology: </strong></p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_9259"
 o:spid="_x0000_i1026" type="#_x0000_t75" style='width:488.25pt;height:210pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="651" height="280" alt="" vspace="0" hspace="0" border="0" style="width:651px;height:280px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" />&nbsp;</p><p>PARAMOUNT:</p><p>A multi-centre, randomised, double-blind, placebo-controlled Phase 3 study (PARAMOUNT), compared the efficacy and safety of continuation maintenance treatment with Pemetrexed injection plus BSC (N = 359) with that of placebo plus BSC (N = 180) in patients with locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC other than predominantly squamous cell histology who did not progress after 4 cycles of first-line doublet therapy of Alix injection in combination with cisplatin. Of the 939 patients treated with Alix injection plus cisplatin induction, 539 patients were randomised to maintenance treatment with Alix or placebo. Of the randomised patients, 44.9% had a complete/partial response and 51.9% had a response of stable disease to pemetrexed injection plus cisplatin induction. Patients randomised to maintenance treatment were required to have an ECOG performance status 0 or 1. The median time from the start of pemetrexed injection plus cisplatin induction therapy to the start of maintenance treatment was 2.96 months on both the Pemetrexed arm and the placebo arm. Randomised patients received maintenance treatment until disease progression. Efficacy and safety were measured from the time of randomisation after completion of first-line (induction) therapy. Patients received a median of 4 cycles of maintenance treatment with Alix injection and 4 cycles of placebo. A total of 169 patients (47.1%) completed &ge; 6 cycles maintenance treatment with Alix injection, representing at least 10 total cycles of&nbsp; Alix injection.</p><p>The study met its primary endpoint and showed a statistically significant improvement in PFS in the Alix injection arm over the placebo arm (N = 472, independently reviewed population; median of 3.9 months and 2.6 months, respectively) (hazard ratio = 0.64, 95% CI = 0.51-0.81, p = 0.0002). The independent review of patient scans confirmed the findings of the investigator assessment of PFS. For randomised patients, as measured from the start of Alix injection plus cisplatin first-line induction treatment, the median investigator-assessed PFS was 6.9 months for the Alix&nbsp; injection arm and 5.6 months for the placebo arm (hazard ratio = 0.59, 95% CI = 0.47-</p><p>0.74).</p><p>Following pemetrexed injection plus cisplatin induction (4 cycles), treatment with pemetrexed injection was statistically superior to placebo for OS (median 13.9 months versus 11.0 months, hazard ratio = 0.78, 95%CI=0.64-0.96, p=0.0195). At the time of this final survival analysis, 28.7% of patients were alive or lost to follow up on the pemetrexed injection arm versus 21.7% on the placebo arm. The relative treatment effect of pemetrexed injection was internally consistent across subgroups (including disease stage, induction response, ECOG PS, smoking status, gender, histology and age) and similar to that observed in the unadjusted OS and PFS analyses. The 1 year and 2 year survival rates for patients on pemetrexed injection were 58% and 32% respectively, compared to 45% and 21% for patients on placebo. From the start of pemetrexed injection plus cisplatin first-line induction treatment, the median OS of patients was</p><p>16.9 months for the Pemetrexed injection arm and 14.0 months for the placebo arm (hazard ratio= 0.78, 95% CI= 0.64-0.96). The percentage of patients that received post-study treatment was 64.3% for Pemetrexed injection and 71.7% for placebo.&nbsp;&nbsp;</p><p>&nbsp;</p><p>PARAMOUNT: Kaplan-Meier plot of progression-free survival (PFS) and Overall Survival (OS) for continuation&nbsp; Pemetrexed&nbsp; injection&nbsp; maintenance&nbsp; versus&nbsp; placebo&nbsp; in&nbsp; patients&nbsp; with&nbsp; NSCLC&nbsp; other&nbsp; than predominantly squamous cell histology (measured from randomisation)</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_11455" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:469.5pt;
 height:261.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="626" height="349" alt="" vspace="0" hspace="0" border="0" style="width:626px;height:349px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" />&nbsp;</p><p>The Pemetrexed injection maintenance safety profiles from the two studies JMEN and PARAMOUNT were similar.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of Pemetrexed following single-agent administration have been evaluated in 426 cancer patients with a variety of solid tumours at doses ranging from 0.2 to 838mg/m2 infused over a 10- minute period. Pemetrexed has a steady-state volume of distribution of 91/m2. In vitro studies indicate that Pemetrexed is approximately 81% bound to plasma proteins. Binding was not notably affected by varying degrees&nbsp; of&nbsp; renal&nbsp; impairment.&nbsp; Pemetrexed&nbsp; undergoes&nbsp; limited&nbsp; hepatic&nbsp; metabolism.&nbsp; Pemetrexed&nbsp; is&nbsp; primarily eliminated in the urine, with 70% to 90% of the administered dose being recovered unchanged in urine within the first 24 hours following administration. In vitro studies indicate that Pemetrexed is actively secreted by OAT3 (organic anion transporter).</p><p>Pemetrexed total systemic clearance is 91.8ml/min and the elimination half-life from plasma is 3.5 hours in patients with normal renal function (creatinine clearance of 90ml/min). Between-patient variability in clearance is moderate at 19.3%. Pemetrexed total systemic exposure (AUC) and maximum plasma concentration increase proportionally with dose. The pharmacokinetics of Pemetrexed are consistent over multiple treatment cycles.&nbsp;</p><p>The pharmacokinetic properties of Pemetrexed are not influenced by concurrently administered cisplatin. Oral folic acid and intramuscular vitamin B<sub>12</sub> supplementation do not affect the pharmacokinetics of Pemetrexed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration of Pemetrexed to pregnant mice resulted in decreased foetal viability, decreased foetal weight, incomplete ossification of some skeletal structures, and cleft palate.</p><p>Administration of Pemetrexed to male mice resulted in reproductive toxicity characterised by reduced fertility rates and testicular atrophy. In a study conducted in beagle dog by intravenous bolus injection for 9 months, testicular findings (degeneration/necrosis of the seminiferous epithelium) have been observed. This suggests that Pemetrexed may impair male fertility. Female fertility was not investigated.</p><p>Pemetrexed was not mutagenic in either the in vitro chromosome aberration test in Chinese hamster ovary cells, or the Ames test. Pemetrexed has been shown to be clastogenic in the in vivo micronucleus test in the mouse.&nbsp;</p><p>Studies to assess the carcinogenic potential of Pemetrexed have not been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The other ingredients are: Mannitol (Pearlitol PF), Sodium Hydroxide, Hydrochloric Acid, Water for injection, Nitrogen gas</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pemetrexed is physically incompatible with diluents containing calcium, including lactated Ringer&#39;s injection and Ringer&#39;s injection. In the absence of other compatibility studies this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.&nbsp;<br />Reconstituted and Infusion Solutions: &nbsp;<br />Reconstituted dilution: To reconstitute 20 mL of 0.9% Sodium chloride Injection (Preservative free) to make a solution containing 25mg/mL Pemetrexed. Reconstituted solution must be further diluted before use.&nbsp;<br />The appropriate volume of reconstituted Pemetrexed solution must be further diluted to 100 ml with sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, and administered as an intravenous infusion over 10 minutes.&nbsp;<br />After reconstitution: The product should be used immediately. When prepared as directed, chemical and physical in-use stability of reconstituted and infusion solutions of Pemetrexed were demonstrated for 24 hours at refrigerated temperature.&nbsp;<br />This medicine is for single use only; any unused solution must be disposed of in accordance with local requirement.&nbsp;<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I glass vial with rubber stopper containing 100mg or 500mg of Pemetrexed. Pack of 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Lab 
Aljameah Street, Malaz quarter, Riyadh 11441 
Saudi Arabia
Tel: +966 11 477 2215
Manufacture:
Hetero Labs Limited Unit-VI, India 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 July,2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>